Paragon's Har­mo­ny Bio­sciences brings in $330M of debt cap­i­tal and eq­ui­ty, look­ing to ex­pand nar­colep­sy drug la­bel

Jeff Aronin’s Har­mo­ny Bio­sciences is ring­ing in a new fi­nanc­ing agree­ment, one that’s bring­ing in hun­dreds of mil­lions of dol­lars.

The Ply­mouth Meet­ing, PA-based biotech has signed a deal with New York in­vest­ment firm Black­stone worth $330 mil­lion, Har­mo­ny an­nounced Tues­day morn­ing as it up­dat­ed in­vestors about its sec­ond quar­ter earn­ings. Funds will come in the form of $300 mil­lion of debt cap­i­tal and $30 mil­lion eq­ui­ty in­vest­ment, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER